報價延遲最少15分鐘:2025/07/21 07:00 EDT
盤前時段
|
||||
|
0.425 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.4151
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.39/-0.78
|
|
企業價值
15.22M
|
| 資產負債 |
|
每股賬面淨值
0.30
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
41.10M
|
|
每股收益
0.95
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/21 07:00 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302. |
